Mucormycosis in adult hematopoietic stem cell transplant recipients during the antifungal prophylaxis era: a single-center retrospective case series
- 1Division of Pulmonary, Critical Care, and Sleep Medicine, Mayo Clinic Health System, Eau Claire, WI USA
- 2Division of Pulmonary, Critical Care, and Sleep Medicine, Mayo Clinic, Rochester, MN USA
Abstract
Background: Mucormycosis is an uncommon but severe invasive fungal infection in hematopoietic stem cell transplant recipients. Contemporary cases may occur outside the classic early neutropenic post-transplant window and during antifungal prophylaxis.
Methods: We performed an International Classification of Diseases code-screened retrospective case series using the institutional denominator of adult hematopoietic stem cell transplant recipients at Mayo Clinic from January 1, 2008, through December 1, 2025. Cases were adjudicated using 2020 European Organization for Research and Treatment of Cancer and Mycoses Study Group Education and Research Consortium criteria. We analyzed transplant characteristics, immune and pulmonary host factors, prophylaxis and therapeutic drug monitoring, diagnostic evidence, management, critical care use, and outcomes.
Results: Among 6,340 adult transplant recipients, 13 met criteria for invasive mucormycosis; eleven had allogeneic transplant and 2 had autologous transplant. Median age was 61 years, and median onset was 681 days after transplant. Underlying conditions included acute myeloid leukemia in 4 patients, chronic lymphocytic leukemia and chronic myeloid leukemia in 2 each, and diffuse large B-cell lymphoma, T-cell lymphoma, acute lymphoblastic leukemia, multiple myeloma, and VEXAS syndrome in one each. All patients were receiving systemic antifungal prophylaxis; 11 were receiving mold-active azoles and 6 were receiving posaconazole. Five patients had pre-diagnosis azole levels available. Neutropenia was present in 4 patients, while lymphopenia, low helper T-cell counts when measured, graft-versus-host disease, targeted or immunomodulatory therapies, and pulmonary host-defense abnormalities were frequent. Pulmonary or mixed pulmonary involvement occurred in 8 patients, disseminated disease in 3, and 9 cases were proven. Liposomal amphotericin B was used in 12 patients, source-control surgery in 6, intensive care unit admission in 6, mechanical ventilation in 5, and all-cause mortality was 5 of 13 at 30, 42, and 90 days.
Conclusions: This series describes mucormycosis in adult transplant recipients rather than establishing causal attribution to transplantation in every case. The findings support diagnostic vigilance for Mucorales infection in chronically immunocompromised transplant recipients, including those remote from transplant, receiving prophylaxis, and without neutropenia.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12879-026-14191-9.
Related
- Surveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis
- Changes in Tacrolimus and Everolimus Trough Concentrations and Dose Requirements After Initiation and Discontinuation of Letermovir Prophylaxis in Kidney Transplant Recipients: A Single-Center Retrospective Study
- Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant
- Infectious complications in kidney transplant recipients across Africa: a scoping review of epidemiology, microbiology, and prophylaxis strategies
- Early Discontinuation of Empiric Antibiotics in Pediatric Haploidentical Hematopoietic Cell Transplant Recipients With Febrile Neutropenia
BibTeX
@article{shiari2026mucormycosis,
title = {{Mucormycosis in adult hematopoietic stem cell transplant recipients during the antifungal prophylaxis era: a single-center retrospective case series}},
author = {Aryan Shiari and Kelly Pennington and Hemang Yadav},
journal = {BMC Infectious Diseases},
year = {2026},
month = aug,
doi = {10.1186/s12879-026-14191-9},
url = {https://doi.org/10.1186/s12879-026-14191-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Mucormycosis in adult hematopoietic stem cell transplant recipients during the antifungal prophylaxis era: a single-center retrospective case series
AU - Aryan Shiari
AU - Kelly Pennington
AU - Hemang Yadav
PY - 2026
DA - 2026/08/07
JO - BMC Infectious Diseases
DO - 10.1186/s12879-026-14191-9
UR - https://doi.org/10.1186/s12879-026-14191-9
AB - Background: Mucormycosis is an uncommon but severe invasive fungal infection in hematopoietic stem cell transplant recipients. Contemporary cases may occur outside the classic early neutropenic post-transplant window and during antifungal prophylaxis. Methods: We performed an International Classification of Diseases code-screened retrospective case series using the institutional denominator of adult hematopoietic stem cell transplant recipients at Mayo Clinic from January 1, 2008, through December 1, 2025. Cases were adjudicated using 2020 European Organization for Research and Treatment of Cancer and Mycoses Study Group Education and Research Consortium criteria. We analyzed transplant characteristics, immune and pulmonary host factors, prophylaxis and therapeutic drug monitoring, diagnostic evidence, management, critical care use, and outcomes. Results: Among 6,340 adult transplant recipients, 13 met criteria for invasive mucormycosis; eleven had allogeneic transplant and 2 had autologous transplant. Median age was 61 years, and median onset was 681 days after transplant. Underlying conditions included acute myeloid leukemia in 4 patients, chronic lymphocytic leukemia and chronic myeloid leukemia in 2 each, and diffuse large B-cell lymphoma, T-cell lymphoma, acute lymphoblastic leukemia, multiple myeloma, and VEXAS syndrome in one each. All patients were receiving systemic antifungal prophylaxis; 11 were receiving mold-active azoles and 6 were receiving posaconazole. Five patients had pre-diagnosis azole levels available. Neutropenia was present in 4 patients, while lymphopenia, low helper T-cell counts when measured, graft-versus-host disease, targeted or immunomodulatory therapies, and pulmonary host-defense abnormalities were frequent. Pulmonary or mixed pulmonary involvement occurred in 8 patients, disseminated disease in 3, and 9 cases were proven. Liposomal amphotericin B was used in 12 patients, source-control surgery in 6, intensive care unit admission in 6, mechanical ventilation in 5, and all-cause mortality was 5 of 13 at 30, 42, and 90 days. Conclusions: This series describes mucormycosis in adult transplant recipients rather than establishing causal attribution to transplantation in every case. The findings support diagnostic vigilance for Mucorales infection in chronically immunocompromised transplant recipients, including those remote from transplant, receiving prophylaxis, and without neutropenia. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12879-026-14191-9.
SN - 1471-2334
ER -